Generic semaglutide takes half of India's market by value in first months
Nine companies launched the day Novo Nordisk's compound patent lapsed, with the cheapest vials undercutting Wegovy and Ozempic sharply.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 8 01:38 ETSource: BioPharma APAC
The wire
- 01After the semaglutide compound patent lapsed on 20 March 2026, Dr Reddy's, Sun, Zydus, Torrent, Alkem, Glenmark, Natco, Eris and USV launched; by April generics held Rs 44 crore of an Rs 88 crore market and 137,000 of 170,000 units.
- 02India now offers a live test of what happens to incretin pricing and volumes once patent protection ends, relevant to supply planning elsewhere.
- 03CDSCO has inspected 49 entities and issued notices over GLP-1 promotion, and prices cited are stated monthly brand prices rather than audited net realisations.
From the source
Read at biopharmaapac.comSemaglutide Generics, Six Months In: Every Launch in India, Every Price, and Where China Stands
Figure 1. India's semaglutide price ladder at 8 October 2026: stated monthly prices by brand, with Novo Nordisk, its licensee and the tirzepatide reference below the line.
